Genetic Testing for Cancer of Inherited Disease Diagnostics
Less than 1/3 of patients receive targeted therapy as less than 1% of mutations in cancer genes are known.
The function of genes and their protein products are intensively studied from both basic science and applied translational perspectives. Of the greater than 250 known cancer ‘driver’ genes, less than 1% of the variants encoding single amino-acid substitutions have known functional or clinical impact. These variants are called Variant of Unknown Significance (VUS) is precisely that – unknown.
Five Facts
- proprietary parallel in vivo process called the GigaAssay
- comprehensively measure the significance of VUSs
- increase accuracy and diagnostic yield of a genetic test
- measure the impact of all possible substitutions
- libraries created in months not years
Gene Mutation Libraries (GMLs) are the solution for determining the impact of variants on function and clinical outcome
Historically, diagnosis uses a small fraction of gene mutations
Now Heligenics modernizes diagnostics with entire gene mutation libraries
Months not years to obtain the critical data to move forward with genetic testing
Heligenics offers a new product to comprehensively measure the significance of VUSs, thereby increasing the accuracy and diagnostic yield of a genetic test. Through a massively parallel in-vivo process called the GigaAssay, Heligenics produces what we call a Gene Mutation/Function Library (GMLs). Each GML measures the impact of all possible amino acid substitutions in the functional target protein. For example, one isoform of BRCA1 has 1816 amino acids, and each position along those 1816 amino acids could be substituted with a VUS encoding any of the 19 other amino acids. To individually test each amino acid substitution by other approaches would be impossible.
Clients can expand their genetic test offering beyond single substitutions in coding regions, by measuring the impact of nucleotide substitutions in 5’ promoter regions, 3’ untranslated regions, and even double single nucleotide variants as grouped haplotypes. The licensees of the GMLs will have a disruptive market advantage that will last for years, if not decades.
Download a Genetic Testing PDF
